Lauxera Capital Partners

Veranex is a global service provider dedicated to the medical technology sector, offering comprehensive, tech-enabled solutions for the entire lifecycle of medical innovations. The company specializes in medical devices, diagnostics, companion diagnostics, digital health, and drug delivery. Veranex provides a range of services, including design and engineering, regulatory support, clinical trials, and market access, allowing clients to expedite their time to market while managing development costs and reducing risks. By focusing solely on the unique needs of the medtech industry, Veranex aims to facilitate the successful commercialization of medical technologies.

Lifen is a healthcare data management platform that facilitates secure communication between health professionals. The company provides a mail assistant that generates secure medical email addresses, reduces paper mail costs, and automates the identification of available communication methods for correspondents. By streamlining medical communication, Lifen enables healthcare practitioners to share and analyze medical data efficiently and securely. The company operates in compliance with regulations and guidelines set by relevant authorities, acting as a subcontractor to physicians or healthcare facilities without owning the data it hosts.

Caresyntax Inc. develops a technology platform specializing in surgical analytics to enhance safety and efficiency in hospitals and ambulatory surgical centers. The company offers solutions designed to identify and manage risks, automate workflows, and reduce variability in surgical procedures. Its flagship products include qvident, a performance management software that enables surgical teams to create and share surgical content, and PRIME365, an integration platform that consolidates key surgical data from various sources such as video, audio, patient vitals, and procedural timestamps. Caresyntax's offerings support a range of surgical procedures, from minimally invasive to robotic surgeries, and can be deployed as HIPAA-compliant software through on-premise, cloud-based, or hybrid installations. Established in 1991, Caresyntax is headquartered in Boston, Massachusetts.

Caresyntax Inc. develops a technology platform specializing in surgical analytics to enhance safety and efficiency in hospitals and ambulatory surgical centers. The company offers solutions designed to identify and manage risks, automate workflows, and reduce variability in surgical procedures. Its flagship products include qvident, a performance management software that enables surgical teams to create and share surgical content, and PRIME365, an integration platform that consolidates key surgical data from various sources such as video, audio, patient vitals, and procedural timestamps. Caresyntax's offerings support a range of surgical procedures, from minimally invasive to robotic surgeries, and can be deployed as HIPAA-compliant software through on-premise, cloud-based, or hybrid installations. Established in 1991, Caresyntax is headquartered in Boston, Massachusetts.

LUMICKS B.V. is a company that specializes in developing advanced equipment for dynamic single-molecule and cell avidity analysis, facilitating research in biology and cancer at the molecular and cellular levels. Founded in 2014 and headquartered in Amsterdam, with an additional office in Cambridge, Massachusetts, LUMICKS offers innovative technologies such as correlative optical tweezers-fluorescence microscopy systems and the C-Trap, which integrates optical tweezers with advanced imaging techniques. The company’s Acoustic Force Spectroscopy (AFS) enables the study of mechanical properties in biological systems, while its u-Flux microfluidics system allows for single-molecule experiments in controlled laminar flow environments. By enabling live measurements and imaging of molecular interactions, LUMICKS provides valuable insights into the fundamental causes of diseases, including cancer, and supports drug optimization efforts.

Reapplix A/S manufactures device for cell therapy that helps patients in wound healing. It offers 3C Patch, a triple layer patch that consists of fibrin for moisture retention and strength, platelets for growth factor release, and leucocytes to orchestrate wound healing and to fight infection. The company was formerly known as Reapplix ApS and changed its name to Reapplix A/S in December 2018. Reapplix A/S was founded in 2008 and is based in Birkerød, Denmark with an additional office in Southlake, Texas.